Cargando…

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer

Tamoxifen is an endocrine treatment for hormone receptor positive breast cancer. The effectiveness of tamoxifen may be compromised in patients with metabolic resistance, who have insufficient metabolic generation of the active metabolites endoxifen and 4-hydroxy-tamoxifen. This has been challenging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helland, Thomas, Alsomairy, Sarah, Lin, Chenchia, Søiland, Håvard, Mellgren, Gunnar, Hertz, Daniel Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000933/ https://www.ncbi.nlm.nih.gov/pubmed/33805613 http://dx.doi.org/10.3390/jpm11030201

Ejemplares similares

The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells
por: Helland, Thomas, et al.
Publicado: (2015)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
por: Chen, Yuanhuang, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
por: Braal, C. Louwrens, et al.
Publicado: (2021)

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
por: Helland, Thomas, et al.
Publicado: (2020)

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Generation of brain tumours in mice by Cre-mediated recombination of neural progenitors in situ with the tamoxifen metabolite endoxifen
por: Benedykcinska, Anna, et al.
Publicado: (2016)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
por: Helland, Thomas, et al.
Publicado: (2017)

Transporting Antitumor Drug Tamoxifen and Its Metabolites, 4-Hydroxytamoxifen and Endoxifen by Chitosan Nanoparticles
por: Agudelo, Daniel, et al.
Publicado: (2013)

Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
por: DeCensi, Andrea, et al.
Publicado: (2021)

Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
por: Braal, C. Louwrens, et al.
Publicado: (2020)

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
por: Buijs, S.M., et al.
Publicado: (2023)

Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients
por: Maggadani, Baitha Palanggatan, et al.
Publicado: (2021)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
por: Dickschen, Kristin, et al.
Publicado: (2014)

Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels
por: Dickschen, Kristin J. R., et al.
Publicado: (2017)

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
por: Nardin, Jeanine Marie, et al.
Publicado: (2019)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles
por: Thorén, Linda, et al.
Publicado: (2020)

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
por: Jager, N. G. L., et al.
Publicado: (2012)

The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
por: Egeland, Nina G., et al.
Publicado: (2015)

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
por: Love, Richard R, et al.
Publicado: (2013)

Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review
por: Eliassen, Finn Magnus, et al.
Publicado: (2023)

Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen
por: Ahmad, A, et al.
Publicado: (2016)

First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study
por: Peccatori, Fedro Alessandro, et al.
Publicado: (2020)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen
por: Kanji, Comfort Ropafadzo, et al.
Publicado: (2023)

Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer
por: Hennig, Ewa E., et al.
Publicado: (2015)

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer
por: Sanchez-Spitman, Anabel Beatriz, et al.
Publicado: (2020)

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
por: Wu, Xianglin, et al.
Publicado: (2011)

Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro
por: Weissenstein, U., et al.
Publicado: (2019)

The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
por: Gingery, Anne, et al.
Publicado: (2014)

Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report
por: Henderson, Sara L., et al.
Publicado: (2016)

Orally administered endoxifen inhibits tumor growth in melanoma-bearing mice
por: Chen, Paul, et al.
Publicado: (2018)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kk43f1kce3fvukvngphsutasnm